However, BACE-1 inhibition might lead to APP (substrates of BACE-1) elevation and impair BACE1-mediated processing of endogenous CHL1 (cell adhesion molecule L1-like protein), exacerbating mechanism-based side effects in, e.g., Down syndrome associated with APP elevation [56]. Here, APP is linked to Down syndrome.